Abstract
Preeclampsia is a cardiovascular disorder of late pregnancy that is, commonly characterized by hypertension, renal structural damage and dysfunction, and fetal growth restriction. Prevailing etiologic models of this disorder include T-cell dysfunction as an initiating cause of preeclampsia. Indoleamine 2,3-dioxygenase (IDO), an enzyme that mediates the conversion of tryptophan to kynurenine, has been linked to preeclampsia in humans, and is known to regulate T-cell activity and an endothelial-derived relaxing factor. To test the hypothesis that IDO is causally involved in the pathogenesis of preeclampsia, mice deficient for IDO (IDO-KO) were generated on a C57BL/6 background. IDO-KO and wild-type C57BL/6 mice were bred, and preeclampsia phenotypes were evaluated during pregnancy. Pregnant IDO-KO mice exhibited pathognomonic renal glomerular endotheliosis, proteinuria, pregnancy-specific endothelial dysfunction, intrauterine growth restriction, and mildly elevated blood pressure compared to wild-type mice. Together these findings highlight an important role for IDO in the generation of phenotypes typical of preeclampsia. Loss of IDO function may represent a risk factor for the development of preeclampsia. By extension, increased IDO activity, reductions in IDO reactants, or increases in IDO products may represent novel therapeutic approaches for this disorder.
Original language | English (US) |
---|---|
Article number | e12257 |
Journal | Physiological Reports |
Volume | 3 |
Issue number | 1 |
DOIs | |
State | Published - 2015 |
Externally published | Yes |
Bibliographical note
Funding Information:This work was supported by grants from the University of Iowa Center for Hypertension Research (to M. K. Santillan, D. A. Santillan, E. J. Devor and J. L. Grobe), University of Iowa Interdisciplinary Immunology Postdoctoral Training Program (T32 AI 007260 to D. A. Santillan and S. M. Scroggins), the National Institutes of Health (HD000849, RR024980 to M. K. Santillan, HL098276 to J. L. Grobe, and HL084207 to C. D. Sigmund), from the American Heart Association (14IRG1871001 to J. L. Grobe and M. K. Santillan), and the University of Iowa Carver Trust (to M. K. Santillan, J. L. Grobe and C. D. Sigmund). The Institute for Clinical and Translational Science at the University of Iowa is supported by the National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program, grant KL2 TR000444. The CTSA program is led by the NIH’s National Center for Advancing Translational Sciences (NCATS). This publication’s contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.
Funding Information:
This work was supported by grants from the University of Iowa Center for Hypertension Research (to M. K. Santillan, D. A. Santillan, E. J. Devor and J. L. Grobe), University of Iowa Interdisciplinary Immunology Postdoctoral Training Program (T32 AI 007260 to D. A. Santillan and S. M. Scroggins), the National Institutes of Health (HD000849, RR024980 to M. K. Santillan, HL098276 to J. L. Grobe, and HL084207 to C. D. Sigmund), from the American Heart Association (14IRG1871001 to J. L. Grobe and M. K. Santillan), and the University of Iowa Carver Trust (to M. K. Santillan, J. L. Grobe and C. D. Sigmund). The Institute for Clinical and Translational Science at the University of Iowa is supported by the National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program, grant KL2 TR000444. The CTSA program is led by the NIH?s National Center for Advancing Translational Sciences (NCATS). This publication?s contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.
Publisher Copyright:
© 2015 the authors.
Keywords
- 3-dioxygenase
- Animal model
- Indoleamine 2
- Preeclampsia
- T cell